Business Context and Reporting Period
This Form 8-K Current Report was filed by Axsome Therapeutics, Inc. on November 9, 2016. The filing discloses the entry into a Material Definitive Agreement and the creation of a direct financial obligation. The Company is a Delaware corporation focused on developing novel therapeutics, with principal executive offices in New York, New York.
Key Financial Metrics and Debt Structure
The Company entered into a Loan and Security Agreement with Silicon Valley Bank (SVB) establishing a term loan facility with an aggregate principal amount of up to $20,000,000. The filing does not provide current revenue, profit, cash flow, or margin data as this is a transactional report rather than a periodic financial statement.
- Total Facility Size: Up to $20,000,000.
- Initial Funding (Term A): $10,000,000, funded no later than November 15, 2016.
- Term B Advance: $5,000,000, contingent on clinical and financial milestones by November 9, 2017.
- Term C Advance: $5,000,000, contingent on Term B achievement and positive Phase 3 data by December 31, 2017.
- Interest Rate: Floating rate of 4.50% above the prime rate.
- Maturity Date: November 1, 2020.
- Repayment Terms: Interest-only for 12 months (extendable to 18 months upon Term B funding), followed by monthly principal and interest payments.
Material Changes and Equity Issuance
In connection with the loan, the Company issued unregistered warrants to SVB and Life Sciences Loans, LLC. This represents a material change in the Company's capital structure and debt obligations.
- Warrant Exercise Price: $7.408333 per share.
- Initial Shares: 32,614 shares per warrant holder exercisable immediately.
- Additional Shares: 6,989 shares per holder upon Term B funding; 6,988 shares per holder upon Term C funding.
- Expiration: November 8, 2023.
- Security Interest: The loan is secured by a first priority interest in substantially all Company assets, excluding intellectual property and certain subsidiary equity stakes.
Covenants and Restrictions
The Loan Agreement imposes significant operational and financial covenants, including prohibitions on:
- Disposing of assets or liquidating.
- Engaging in business combinations or acquisitions.
- Incurring additional indebtedness.
- Paying dividends or making payments on subordinated debt.
- Granting security interests in intellectual property.
Outlook, Risks, and Milestones
Future funding tranches are strictly tied to specific clinical and financial milestones, creating execution risk for the Company.
- Clinical Milestone: Receipt of positive interim results from the Phase 3 CREATE-1 Study (AXS-02 for complex regional pain syndrome) by November 9, 2017, and positive data sufficient for a New Drug Application (NDA) filing by December 31, 2017.
- Financial Milestone: Receipt of at least $30,000,000 in net cash proceeds from an equity issuance.
- Risk: Failure to meet these milestones will prevent the Company from accessing the remaining $10,000,000 of the loan facility.
Investor Verification Checklist
- Verify the status of the Phase 3 CREATE-1 Study and the timeline for interim results.
- Confirm the Company's ability to raise $30,000,000 in equity proceeds by November 2017.
- Review the impact of the 4.50% + prime interest rate on future cash flow projections.
- Assess the dilution impact of the warrants (up to 46,591 shares per holder) if fully exercised.
- Monitor compliance with restrictive covenants, particularly the prohibition on additional debt and acquisitions.